Perspective Therapeutics Reports Promising Phase I/IIa Clinical Trial Results for [212Pb]VMT-α-NET in Advanced Neuroendocrine Tumors

Key Highlights from the Report

• Study Drug: [212Pb]VMT-α-NET, an alpha therapy agent targeting SSTR2-expressing neuroendocrine tumors (NETs)
• Trial Design: Prospective, open-label, Phase I/IIa clinical trial evaluating safety, tolerability, pharmacokinetics, and efficacy
• Patient Population: 64 patients with advanced SSTR2+ neuroendocrine tumors treated as of data cutoff (March 4, 2026)
• Principal Investigators: Multicenter participation including Mayo Clinic, Washington University School of Medicine, Ohio State University, Johns Hopkins, and others

Detailed Clinical Results

• Tolerability and Safety:
  • No dose-limiting toxicities (DLTs)
  • No grade 4 or 5 adverse events
  • No dysphagia or treatment-related discontinuations
  • No serious renal complications
  • No clinically significant treatment-related myelosuppression
  • Blood creatinine increases (marker for kidney function) were observed as grade 1 adverse events in 11 subjects (all mild; 4 recovered, 7 ongoing)
  • Serious adverse events occurred in five patients, none related to the study drug (pyrexia and vomiting, decreased cardiac output, foot fracture, pancreatitis, influenza-like illness)
  • Grade 3 adverse events were seen in 36% of patients (23/64), with no grade 4 events reported. All patients (100%) experienced some treatment-emergent adverse event, as is typical in oncology trials.
• Patient Demographics:
  • Median age: 62.5 years (range: 37–78)
  • Gender: 39% female, 61% male
  • Race: Majority White (92.2%), with small representation from Black (1.6%), Asian (3.1%), and multiple races (3.1%)
  • Performance Status: 78.1% ECOG 0, 21.9% ECOG 1
  • Median time from diagnosis to enrollment: 38.4 months (range: 5–317 months)
  • Most patients had gastroenteropancreatic NETs (GEP-NETs), including both pancreatic and non-pancreatic subtypes
  • Disease grade: 20% G1, 67% G2, 13% G3
  • Most commonly used prior therapies: Somatostatin analogues (84.4%), chemotherapy (25%), small molecule therapy (14.1%), immunotherapy (3.1%)
• Most Common Treatment-Emergent Adverse Events (≥15% incidence):
  • Fatigue (66%)
  • Alopecia (66%)
  • Nausea (64%)
  • Diarrhea (63%)
  • Anemia (42%)
  • Lymphocyte count decreased (36%)
  • Others: abdominal pain, increased liver enzymes, hypertension
• Efficacy Data and Clinical Activity:
  • 18 of 25 patients (72%) in Cohorts 1 and 2 (first half) remained progression-free at data cutoff
  • Investigator-assessed RECIST v1.1 objective response rate: 43% (10/23 patients in first half of Cohort 2; 9 confirmed, 1 unconfirmed)
  • Two patients in Cohort 1 (2.5 mCi dose) had stable disease for 2 years
  • Continued tumor shrinkage observed in 9 patients after ESMO 2025; 1 new unconfirmed partial response (PR) at week 60
  • Ongoing follow-up in Cohort 2; treatment ongoing for patients in Cohort 3 (6 mCi dose level)

Study Design and Dosing

• Cohort 1: 2.5 mCi (n=2)
• Cohort 2: 5 mCi (n=46; split into two halves)
• Cohort 3: 6 mCi (n=16)
• Majority of patients received 4 doses over a median follow-up period ranging from 15.6 to 96.4 weeks depending on cohort

Implications for Investors

• This trial update demonstrates that [212Pb]VMT-α-NET is both active and well-tolerated in patients with advanced neuroendocrine tumors, with a substantial proportion achieving objective responses and prolonged progression-free survival.
• No new safety signals, dose-limiting toxicities, or serious treatment-related adverse events have emerged, supporting the ongoing development of this agent.
• The 43% objective response rate in a difficult-to-treat population is a potentially price-sensitive and share-moving result, as it underscores the agent’s competitive positioning in the NET therapy landscape.
• Ongoing enrollment and follow-up in higher-dose cohorts (6 mCi) may yield further efficacy and durability data in future updates, which investors should monitor closely.
• All data are as of March 4, 2026; future readouts could provide additional catalysts for share movement.

Conclusion

Perspective Therapeutics’ [212Pb]VMT-α-NET continues to demonstrate a favorable safety profile and promising anti-tumor activity in advanced SSTR2+ NETs. The absence of severe adverse events, coupled with meaningful response rates and durable disease control, make this an important update for shareholders and potential investors. As the company continues to enroll and follow patients at higher doses, additional data may further validate the therapy’s value proposition and impact the company’s valuation.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with a licensed financial advisor before making investment decisions. Forward-looking statements are subject to significant risks and uncertainties.

View Perspective Therapeutics, Inc. Historical chart here